King Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From King Pharmaceuticals, Inc.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
Novartis Committed To Carving Out More Indications For Cosentyx
The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”
Acelyrin Enters The Spotlight As NASDAQ Debut Dawns
The US biotech intends to use the proceeds from its upcoming IPO to advance lead candidate izokibep, an interleukin-17A inhibitor that is showing potential as a treatment for hidradenitis suppurativa.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
- Medical Devices
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Alpharma Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.